newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting

Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients Poster with additional data from Phase 2 study follow-up to be presented at ASN Talaris to host investor conference call on Novembe